| Literature DB >> 27569214 |
Andrew G Schache1,2, Ned G Powell3, Kate S Cuschieri4, Max Robinson5, Sam Leary6, Hisham Mehanna7, Davy Rapozo8, Anna Long9, Heather Cubie4, Elizabeth Junor10, Hannah Monaghan11, Kevin J Harrington12,13, Christopher M Nutting13, Ulrike Schick12,13, Andy S Lau1,2, Navdeep Upile1,2, Jon Sheard14, Kath Brougham14, Catharine M L West15, Ken Oguejiofor15, Steve Thomas16, Andy R Ness6, Miranda Pring16, Gareth J Thomas17, Emma V King18, Dennis J McCance19, Jacqueline A James20, Michael Moran21, Phil Sloan5, Richard J Shaw1,2, Mererid Evans22, Terry M Jones23,2.
Abstract
A rising incidence of oropharyngeal squamous cell carcinoma (OPSCC) incidence has occurred throughout the developed world, where it has been attributed to an increasing impact of human papillomavirus (HPV) on disease etiology. This report presents the findings of a multicenter cross-sectional retrospective study aimed at determining the proportion of HPV-positive and HPV-negative OPSCC within the United Kingdom. Archival tumor tissue blocks from 1,602 patients previously diagnosed with OPSCC (2002-2011) were collated from 11 centers. HPV status was determined with three validated commercial tests to provide valid data for 1,474 cases in total. Corresponding national incidence data from the same decade were obtained from UK Cancer registries. The overall proportion of HPV+ OPSCC between 2002 and 2011 was 51.8% [95% confidence interval (CI), 49.3-54.4], and this remained unchanged throughout the decade [unadjusted RR = 1.00 (95% CI, 0.99-1.02)]. However, over the same period, the incidence of OPSCC in the broader UK population underwent a 2-fold increase [age-standardized rate 2002: 2.1 (95% CI, 1.9-2.2); 2011: 4.1 (95% CI, 4.0-4.3)]. Although the number of OPSCCs diagnosed within the United Kingdom from 2002 to 2011 nearly doubled, the proportion of HPV+ cases remained static at approximately 50%. Our results argue that the rapidly increasing incidence of OPSCC in the United Kingdom cannot be solely attributable to the influence of HPV. The parallel increase in HPV+ and HPV- cases we documented warrants further investigation, so that appropriate future prevention strategies for both types of disease can be implemented. Cancer Res; 76(22); 6598-606. ©2016 AACR. ©2016 American Association for Cancer Research.Entities:
Mesh:
Year: 2016 PMID: 27569214 PMCID: PMC9158514 DOI: 10.1158/0008-5472.CAN-16-0633
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 13.312